HOXD13 and cancer: In the meantime, patients with a variety of malignancies have higher levels of sPD-1 in their blood and pretherapeutic increase is associated to higher risk of cancer developing, the progression of the disease and a worse result, on the other hand, a stable or elevated sPD-1 levels following cancer treatment have been linked to better outcomes (5, 10, 11).